Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces e...
用于治疗由慢性肾脏病(CKD)导致的肾性贫血,包括透析和非透析CKD患者。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.